Pavelock Natalie, Masood Umair, Minchenberg Scott, Heisig David
Department of Gastroenterology, State University of New York Upstate Medical UniversitySyracuseNew York.
College of Medicine, State University of New York Upstate Medical UniversitySyracuseNew York.
Proc (Bayl Univ Med Cent). 2019 Feb 1;32(1):14-17. doi: 10.1080/08998280.2018.1542887. eCollection 2019 Jan.
Obesity is increasingly common among patients with inflammatory bowel disease (IBD). The interplay between proinflammatory states of obesity and the course of IBD is yet to be elucidated. We conducted a retrospective study of 55 patients with IBD over the course of 5 years (2012 to 2017). We documented various clinical outcomes (mean number of clinic visits, hospitalizations/flares, procedures, and escalations in therapy) based on three initial weight groups: normal weight, overweight, and obese. There was an increasing trend in all clinical outcomes with increasing weight and a statistically significant difference in mean clinic visits ( = 0.048) and mean hospitalizations/flares ( = 0.004) when comparing normal-weight to obese individuals. Our study suggests that obesity influences burden of disease and treatment in IBD. This should encourage clinicians to treat obesity in IBD patients as an active problem because it may help improve clinical outcomes.
肥胖在炎症性肠病（IBD）患者中越来越常见。肥胖的促炎状态与IBD病程之间的相互作用尚待阐明。我们对55例IBD患者进行了为期5年（2012年至2017年）的回顾性研究。我们根据三个初始体重组记录了各种临床结果（平均门诊就诊次数、住院/病情发作、手术和治疗升级情况）：正常体重、超重和肥胖。随着体重增加，所有临床结果均呈上升趋势，比较正常体重者与肥胖者时，平均门诊就诊次数（P = 0.048）和平均住院/病情发作次数（P = 0.004）存在统计学显著差异。我们的研究表明，肥胖会影响IBD的疾病负担和治疗。这应促使临床医生将IBD患者的肥胖视为一个亟待解决的问题，因为这可能有助于改善临床结果。
